US inflation unexpectedly cooled in November, according to a delayed report, although economists warned against reading too much into the numbers because of gaps in the data. The Consumer Price Index ...

The latest Consumer Price Index was below what economists had expected and likely reflects what they called distortions caused by the government shutdown. Note: Data for October 2025 is missing ...

The consumer price index rose at a 2.7% annualized rate last month, a delayed report from the Bureau of Labor Statistics showed. Economists polled by Dow Jones expected the CPI to have risen 3.1%. The ...

Inflation in November fell to 2.7%, the Bureau of Labor Statistics said Thursday, a positive sign for consumers on its face. However, November’s data was collected later than normal. The released ...

Prices climbed 2.7% in November compared to a year earlier. Inflation dropped in November, ending a monthslong acceleration of price increases and offering relief for households strained by cost hikes ...

Data collection issues skewed the latest Consumer Price Index report, economists warned, clouding the picture for the Federal Reserve as it also grapples with a cooling labor market. By Colby Smith ...

Inflation unexpectedly – and sharply – slowed in November, a seemingly welcome change for Americans weighed down by the persistently high cost of living. However, economists were quick to caution ...

We explained why this project requires more scrutiny in a Dec. 4 editorial (the commission was initially set to vote on the contracts Dec. 5). But with the vote now just a day away, we're recapping ...

The company building an AI data center in West Feliciana Parish said early Wednesday that Anthropic, whose Claude chatbot is a rival to Chat GPT, has signed a long-term deal to use the facility, ...

Lawmakers and the legal community are raising questions after a Minnesota judge took the uncommon step of overturning a unanimous jury verdict in a massive $7.2 million Medicaid fraud case, a move ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...